Drugs in Dev. Cardiology/Vascular Diseases
Phase II
Netherlands 
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C, if approved. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin...
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Obicetrapib (TA-8995) is an oral, low-dose and once-daily CETP inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combina...
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ROSE2 study evaluates obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, in combination with ezetimibe, a cholesterol absorption inhibitor, in patients who are currently receiving high-intensity statin therapy.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Obicetrapib,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NewAmsterdam Pharma Reports Positive Data in Phase II Dyslipidemia Trial
Details : Results of ROSE study demonstrated that patients on statin therapy who received 5mg of obicetrapib saw a reduction in LDL-c of 42% and patients who were part of the 10mg cohort experienced 51% reduction v/s baseline, while the placebo experienced 7% redu...
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2021
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NewAmsterdam Reports Positive Results from Phase 2 Study of Oral Obicetrapib
Details : ROSE was designed as a placebo-controlled, double-blind, randomized, Phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2021
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Morningside Ventures
Deal Size : $196.0 million
Deal Type : Series A Financing
Details : Funding will support initiation and finalization of Phase 3 development of obicetrapib, a potent ApoB and LDL-c lowering small molecule drug, intended for patients not well-controlled on statins.
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 14, 2021
Lead Product(s) : Obicetrapib
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Morningside Ventures
Deal Size : $196.0 million
Deal Type : Series A Financing
Reset All
